AR087227A1 - CONJUGADO DE INTERFERON a CON POLIETILENGLICOL - Google Patents
CONJUGADO DE INTERFERON a CON POLIETILENGLICOLInfo
- Publication number
- AR087227A1 AR087227A1 ARP110102606A ARP110102606A AR087227A1 AR 087227 A1 AR087227 A1 AR 087227A1 AR P110102606 A ARP110102606 A AR P110102606A AR P110102606 A ARP110102606 A AR P110102606A AR 087227 A1 AR087227 A1 AR 087227A1
- Authority
- AR
- Argentina
- Prior art keywords
- conjugate
- formula
- ifn
- interferon
- peg
- Prior art date
Links
- 102000014150 Interferons Human genes 0.000 title abstract 4
- 108010050904 Interferons Proteins 0.000 title abstract 4
- 229940079322 interferon Drugs 0.000 title abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 3
- 239000002202 Polyethylene glycol Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000031018 biological processes and functions Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 239000013589 supplement Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se relaciona con el ámbito de la industria farmacéutica y medicina, particularmente con los PEG-derivados de interferones y se refiere a la creación de un conjugado de interferón con polietilenglicol, funcionalmente activo, altamente depurado, estable, con la actividad del interferón a, inmunogenicidad disminuida, acción biológica prolongada y parámetros farmacocinéticas mejorados de fórmula común (1), donde: n - valores enteros de 227 a 10000 de forma tal que la masa molecular de PEG es de aproximadamente 10000 - 40000 Da; m - valor entero ³ 4; IFN - polipéptido natural o recombinante, que posee actividad IFN-a. También la presente se refiere a medicamentos, que contengan el conjugado de la fórmula (1) presentada, composiciones farmacéuticas, que puedan aplicarse para el tratamiento de enfermedades virales y oncológicas, acompañadas por estado inmuno deficitario primario o secundario, que contenga el conjugado PEG-IFN presentado y complementos auxiliares aceptados. La presente se refiere a la aplicación del conjugado de la fórmula (1) para la obtención de un medicamento que posea una actividad antiviral, antiproliferativa e inmuno modulara, al método de profilaxis y/o tratamiento de enfermedades acompañadas con estado inmuno deficitario primario o secundario, que incluya la introducción de una cantidad terapéuticamente eficiente del conjugado de la fórmula (1), y el contenedor que incluya la composición farmacéutica y el conjunto correspondiente.Reivindicación 1: El conjugado estable de interferón-a PEGilado de fórmula (1), que representa un solo isómero posicional, donde: n - valores enteros de 227 a 10000; m - valor entero ³ 4; Na-H-IFN - interferón-a.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2010129824/10A RU2447083C1 (ru) | 2010-07-20 | 2010-07-20 | НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087227A1 true AR087227A1 (es) | 2014-03-12 |
Family
ID=45497062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102606A AR087227A1 (es) | 2010-07-20 | 2011-07-19 | CONJUGADO DE INTERFERON a CON POLIETILENGLICOL |
Country Status (21)
| Country | Link |
|---|---|
| KR (1) | KR101586372B1 (es) |
| CN (1) | CN102617736B (es) |
| AR (1) | AR087227A1 (es) |
| BR (1) | BRPI1101565A2 (es) |
| CO (1) | CO6680611A2 (es) |
| CR (1) | CR20130021A (es) |
| CU (1) | CU24193B1 (es) |
| DO (1) | DOP2013000002A (es) |
| EA (1) | EA020257B1 (es) |
| EC (1) | ECSP13012398A (es) |
| HK (1) | HK1170504A1 (es) |
| MX (1) | MX2011007458A (es) |
| MY (1) | MY168784A (es) |
| NI (1) | NI201300008A (es) |
| PE (1) | PE20131034A1 (es) |
| PH (1) | PH12012502425A1 (es) |
| RU (1) | RU2447083C1 (es) |
| SG (1) | SG187117A1 (es) |
| UA (1) | UA99766C2 (es) |
| UY (1) | UY33525A (es) |
| WO (1) | WO2012011836A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2515913C1 (ru) * | 2013-03-22 | 2014-05-20 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") | ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ) |
| EA021643B1 (ru) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа |
| EA021610B1 (ru) * | 2013-03-28 | 2015-07-30 | Илья Александрович МАРКОВ | Жидкое противовирусное лекарственное средство |
| CN103463623B (zh) * | 2013-09-03 | 2015-09-09 | 长春海伯尔生物技术有限责任公司 | 一种聚乙二醇干扰素注射液及其制备方法 |
| RU2554761C1 (ru) * | 2014-05-13 | 2015-06-27 | Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" | Противоэнтеровирусное и иммуностимулирующее средство |
| RU2572800C1 (ru) * | 2014-09-22 | 2016-01-20 | Закрытое Акционерное Общество "Биокад" | Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении |
| EA029498B1 (ru) * | 2015-11-24 | 2018-04-30 | Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) | ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ |
| RU2678332C1 (ru) | 2017-09-08 | 2019-01-28 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") | Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения |
| EP4139343A4 (en) * | 2020-04-20 | 2024-06-12 | National Research Council of Canada | Recombinant interferon |
| CN114392237B (zh) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | 一种冻干病毒制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5951974A (en) * | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
| JP2758154B2 (ja) * | 1995-04-06 | 1998-05-28 | エフ・ホフマン−ラ ロシユ アーゲー | インターフェロンを含む液体製剤 |
| TW517067B (en) * | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| CA2498167C (en) * | 2002-09-09 | 2012-03-20 | Nektar Therapeutics Al, Corporation | Water-soluble polymer alkanals |
| RU2311930C2 (ru) * | 2004-04-30 | 2007-12-10 | Закрытое акционерное общество "ВЕРОФАРМ" | Пэгилированный интерферон для борьбы с вирусной инфекцией |
| US20060029573A1 (en) * | 2004-06-30 | 2006-02-09 | Chun Shen | Pegylated interferon alpha-1b |
| AU2006269845B2 (en) * | 2005-07-19 | 2012-03-22 | Nektar Therapeutics | Method for preparing polymer maleimides |
| EP2044097A4 (en) * | 2006-06-23 | 2010-10-06 | Quintessence Biosciences Inc | MODIFIED RIBONUCLEASES |
| CN101491682A (zh) * | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
| CN101591387A (zh) * | 2008-05-28 | 2009-12-02 | 中国人民解放军军事医学科学院微生物流行病研究所 | 聚乙二醇化重组人干扰素ω偶合物 |
| CN101514229B (zh) * | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
-
2010
- 2010-07-20 RU RU2010129824/10A patent/RU2447083C1/ru active
- 2010-09-24 WO PCT/RU2010/000529 patent/WO2012011836A1/en active Application Filing
- 2010-09-24 PE PE2013000084A patent/PE20131034A1/es not_active Application Discontinuation
- 2010-09-24 CU CUP2013000013A patent/CU24193B1/es active IP Right Grant
- 2010-09-24 MY MYPI2013000216A patent/MY168784A/en unknown
- 2010-09-24 KR KR1020137001858A patent/KR101586372B1/ko not_active Expired - Fee Related
- 2010-09-24 PH PH1/2012/502425A patent/PH12012502425A1/en unknown
- 2010-09-24 SG SG2013003801A patent/SG187117A1/en unknown
- 2010-12-15 UA UAA201015114A patent/UA99766C2/uk unknown
-
2011
- 2011-04-01 BR BRPI1101565-9A patent/BRPI1101565A2/pt not_active IP Right Cessation
- 2011-06-21 EA EA201100809A patent/EA020257B1/ru not_active IP Right Cessation
- 2011-07-12 MX MX2011007458A patent/MX2011007458A/es active IP Right Grant
- 2011-07-19 AR ARP110102606A patent/AR087227A1/es unknown
- 2011-07-19 CN CN201110214149.6A patent/CN102617736B/zh not_active Expired - Fee Related
- 2011-07-20 UY UY0001033525A patent/UY33525A/es unknown
-
2012
- 2012-11-07 HK HK12111241.0A patent/HK1170504A1/zh not_active IP Right Cessation
-
2013
- 2013-01-04 DO DO2013000002A patent/DOP2013000002A/es unknown
- 2013-01-18 CR CR20130021A patent/CR20130021A/es unknown
- 2013-01-18 NI NI201300008A patent/NI201300008A/es unknown
- 2013-01-18 EC ECSP13012398 patent/ECSP13012398A/es unknown
- 2013-01-18 CO CO13009157A patent/CO6680611A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2010129824A (ru) | 2012-01-27 |
| KR20130056885A (ko) | 2013-05-30 |
| EA201100809A1 (ru) | 2012-01-30 |
| CN102617736A (zh) | 2012-08-01 |
| UY33525A (es) | 2012-02-29 |
| CU20130013A7 (es) | 2013-04-19 |
| BRPI1101565A2 (pt) | 2012-12-04 |
| RU2447083C1 (ru) | 2012-04-10 |
| DOP2013000002A (es) | 2013-09-15 |
| ECSP13012398A (es) | 2013-05-31 |
| EA020257B1 (ru) | 2014-09-30 |
| UA99766C2 (uk) | 2012-09-25 |
| CU24193B1 (es) | 2016-09-30 |
| MX2011007458A (es) | 2012-01-19 |
| PE20131034A1 (es) | 2013-09-27 |
| NI201300008A (es) | 2014-05-26 |
| CR20130021A (es) | 2013-02-20 |
| CN102617736B (zh) | 2015-11-25 |
| SG187117A1 (en) | 2013-02-28 |
| HK1170504A1 (zh) | 2013-03-01 |
| WO2012011836A1 (en) | 2012-01-26 |
| PH12012502425A1 (en) | 2013-07-08 |
| KR101586372B1 (ko) | 2016-01-18 |
| CO6680611A2 (es) | 2013-05-31 |
| MY168784A (en) | 2018-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087227A1 (es) | CONJUGADO DE INTERFERON a CON POLIETILENGLICOL | |
| DOP2011000343A (es) | Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral | |
| WO2009033665A3 (en) | Use of a rgd-peptide and/or parathyroid hormone (1-34 ) as anti-hiv agent | |
| EA201290395A1 (ru) | Иммуномодулирующие полипептиды, полученные из il-2, и их применение для лечения рака и хронических инфекций | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| WO2009033784A3 (en) | Use of apelin-13 (qrprlshkgpmpf) and optionally aplha-casein (90-96) as a therapeutic agents in eg the treatment of hiv infection | |
| MX2010002557A (es) | Interferon alfa 2b modificado por glicol de polietileno, la preparacion y el uso del mismo. | |
| WO2009043458A3 (en) | Use of oxytocin to treat many diseases | |
| WO2009033785A3 (en) | Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hiv infection | |
| EA200800467A1 (ru) | Применение сложных эфиров гидроксибензойной кислоты и аналогов для получения лекарственного средства для предупреждения и лечения вирусной инфекции | |
| RU2013148779A (ru) | Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени | |
| JP2013541521A5 (es) | ||
| BR112022010574A2 (pt) | Composições farmacêuticas compreendendo cabotegravir | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| NZ704285A (en) | Protozoan variant-specific surface proteins (vsp) as carriers for oral drug delivery | |
| MX2021015966A (es) | Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria. | |
| AR117715A1 (es) | Interferón hiperglicosilado con inmunogenicidad reducida | |
| JP2013542196A5 (es) | ||
| WO2009033666A3 (en) | Use of parathyroid hormone ( 1-34 ) as anti-hiv agent | |
| WO2014014389A3 (ru) | Композиция в форме геля для профилактики и лечения пародонта | |
| MX2024008242A (es) | Composiciones que contienen fexofenadina. | |
| MD3121G2 (ro) | Metodă de profilaxie a hepatitei virale B | |
| CN115667291A (zh) | 一种白细胞介素29突变体蛋白 | |
| RU2014140049A (ru) | МОЛЕКУЛА ИНТЕРФЕРОНА-β-1a ЧЕЛОВЕКА, МОДИФИЦИРОВАННАЯ ПОЛИЭТИЛЕНГЛИКОЛЕМ, ОБЛАДАЮЩАЯ ПРОТИВОВИРУСНОЙ, ИММУНОМОДУЛИРУЮЩЕЙ И АНТИПРОЛИФЕРАТИВНОЙ АКТИВНОСТЯМИ, С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ, УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, УЛУЧШЕННЫМИ ФАРМАКОКИНЕТИЧЕСКИМИ И ФАРМАКОДИНАМИЧЕСКИМИ ПАРАМЕТРАМИ, ПРИГОДНАЯ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕЕ ОСНОВЕ | |
| Mandorfer | Boceprevir/peginterferon-alfa-2a/ribavirin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |